1354 related articles for article (PubMed ID: 16112249)
1. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
[TBL] [Abstract][Full Text] [Related]
2. Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis.
Pelletier EM; Shim B; Goodman S; Amonkar MM
Breast Cancer Res Treat; 2008 Mar; 108(2):297-305. PubMed ID: 17577662
[TBL] [Abstract][Full Text] [Related]
3. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
[TBL] [Abstract][Full Text] [Related]
4. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
[TBL] [Abstract][Full Text] [Related]
5. Economic burden of metastatic bone disease in the U.S.
Schulman KL; Kohles J
Cancer; 2007 Jun; 109(11):2334-42. PubMed ID: 17450591
[TBL] [Abstract][Full Text] [Related]
6. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
7. Economic burden prior to COPD diagnosis: a matched case-control study in the United States.
Akazawa M; Halpern R; Riedel AA; Stanford RH; Dalal A; Blanchette CM
Respir Med; 2008 Dec; 102(12):1744-52. PubMed ID: 18760581
[TBL] [Abstract][Full Text] [Related]
8. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
9. Cost of atrial fibrillation in United States managed care organizations.
Kim MH; Lin J; Hussein M; Kreilick C; Battleman D
Adv Ther; 2009 Sep; 26(9):847-57. PubMed ID: 19768638
[TBL] [Abstract][Full Text] [Related]
10. Utilization and cost of health care services associated with primary malignant brain tumors in the United States.
Kutikova L; Bowman L; Chang S; Long SR; Thornton DE; Crown WH
J Neurooncol; 2007 Jan; 81(1):61-5. PubMed ID: 16773215
[TBL] [Abstract][Full Text] [Related]
11. Estimation of economic costs associated with transfusion dependence in adults with MDS.
Frytak JR; Henk HJ; De Castro CM; Halpern R; Nelson M
Curr Med Res Opin; 2009 Aug; 25(8):1941-51. PubMed ID: 19552620
[TBL] [Abstract][Full Text] [Related]
12. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
13. Resource utilization for ovarian cancer patients at the end of life: how much is too much?
Lewin SN; Buttin BM; Powell MA; Gibb RK; Rader JS; Mutch DG; Herzog TJ
Gynecol Oncol; 2005 Nov; 99(2):261-6. PubMed ID: 16140364
[TBL] [Abstract][Full Text] [Related]
14. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data.
Lee WC; Balu S; Cobden D; Joshi AV; Pashos CL
Clin Ther; 2006 Oct; 28(10):1712-25; discussion 1710-1. PubMed ID: 17157128
[TBL] [Abstract][Full Text] [Related]
15. Assessing incidence and economic burden of genital warts with data from a US commercially insured population.
Hoy T; Singhal PK; Willey VJ; Insinga RP
Curr Med Res Opin; 2009 Oct; 25(10):2343-51. PubMed ID: 19650749
[TBL] [Abstract][Full Text] [Related]
16. Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in Medicaid-enrolled patients with type 2 diabetes mellitus.
Balkrishnan R; Arondekar BV; Camacho FT; Shenolikar RA; Horblyuk R; Anderson RT
Clin Ther; 2007 Jun; 29(6 Pt 1):1306-15. PubMed ID: 18036392
[TBL] [Abstract][Full Text] [Related]
17. Burden of schizophrenia in recently diagnosed patients: healthcare utilisation and cost perspective.
Nicholl D; Akhras KS; Diels J; Schadrack J
Curr Med Res Opin; 2010 Apr; 26(4):943-55. PubMed ID: 20163295
[TBL] [Abstract][Full Text] [Related]
18. Costs of gastrointestinal events after outpatient opioid treatment for non-cancer pain.
Kwong WJ; Diels J; Kavanagh S
Ann Pharmacother; 2010 Apr; 44(4):630-40. PubMed ID: 20197473
[TBL] [Abstract][Full Text] [Related]
19. Empiric investigation on direct costs-of-illness and healthcare utilization of Medicaid patients with diabetes mellitus.
Guo JJ; Gibson JT; Gropper DM; Oswald SL; Barker KN
Am J Manag Care; 1998 Oct; 4(10):1433-46. PubMed ID: 10338736
[TBL] [Abstract][Full Text] [Related]
20. The annual impact of seasonal influenza in the US: measuring disease burden and costs.
Molinari NA; Ortega-Sanchez IR; Messonnier ML; Thompson WW; Wortley PM; Weintraub E; Bridges CB
Vaccine; 2007 Jun; 25(27):5086-96. PubMed ID: 17544181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
